By the same authors

From the same journal

From the same journal

Phospholipase D2 in prostate cancer: protein expression changes with Gleason score

Research output: Contribution to journalArticlepeer-review

Published copy (DOI)

Author(s)

Department/unit(s)

Publication details

JournalBritish journal of cancer
DateAccepted/In press - 1 Oct 2019
DateE-pub ahead of print - 1 Nov 2019
DatePublished (current) - Dec 2019
Issue number12
Volume121
Number of pages11
Pages (from-to)1016-1026
Early online date1/11/19
Original languageEnglish

Abstract

BACKGROUND: Phospholipases D1 and D2 (PLD1/2) are implicated in tumorigenesis through their generation of the signalling lipid phosphatidic acid and its downstream effects. Inhibition of PLD1 blocks prostate cell growth and colony formation. Here a role for PLD2 in prostate cancer (PCa), the major cancer of men in the western world, is examined.

METHODS: PLD2 expression was analysed by immunohistochemistry and western blotting. The effects of PLD2 inhibition on PCa cell viability and cell motility were measured using MTS, colony forming and wound-healing assays.

RESULTS: PLD2 protein is expressed about equally in luminal and basal prostate epithelial cells. In cells from different Gleason-scored PCa tissue PLD2 protein expression is generally higher than in non-tumorigenic cells and increases in PCa tissue scored Gleason 6-8. PLD2 protein is detected in the cytosol and nucleus and had a punctate appearance. In BPH tissue stromal cells as well as basal and luminal cells express PLD2. PLD2 protein co-expresses with chromogranin A in castrate-resistant PCa tissue. PLD2 inhibition reduces PCa cell viability, colony forming ability and directional cell movement.

CONCLUSIONS: PLD2 expression correlates with increasing Gleason score to GS8. PLD2 inhibition has the potential to reduce PCa progression.

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations